World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 12 March 2024
Main ID:  EUCTR2016-004408-76-DE
Date of registration: 06/06/2017
Prospective Registration: Yes
Primary sponsor: Merck Sharp & Dohme LLC
Public title: A Phase III, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) (SCH-900475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-585)
Scientific title: A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) - Phase III Trial of Pembrolizumab + Chemotherapy in Participants with Gastric or GEJ Adenocarcinoma
Date of first enrolment: 25/08/2017
Target sample size: 1000
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004408-76
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: Main study + FLOT cohort If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 4  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Brazil Canada Chile Estonia France Germany Israel
Italy Japan Korea, Republic of Latvia Lithuania Poland Russian Federation Singapore
Taiwan United Kingdom United States
Contacts
Name: Chie-Schin Shih   
Address:  126 East Lincoln Ave., P.O. Box 2000 07065 Rahway, NJ United States
Telephone: +1(267) 3056836
Email: chie-schin.shih@merck.com
Affiliation:  Merck Sharp & Dohme LLC
Name: Chie-Schin Shih   
Address:  126 East Lincoln Ave., P.O. Box 2000 07065 Rahway, NJ United States
Telephone: +1(267) 3056836
Email: chie-schin.shih@merck.com
Affiliation:  Merck Sharp & Dohme LLC
Key inclusion & exclusion criteria
Inclusion criteria:
1.Have previously untreated localized gastric or GEJ adenocarcinoma as defined by T3 or greater primary lesion or the presence of any positive nodes N+ (clinical nodes) without evidence of metastatic disease. Siewert type 2 or 3 tumors are eligible. Enrollment of participants with Siewert type 1 tumors will be limited to those for whom the planned treatment is perioperative chemotherapy and resection. Tumor staging prior to enrollment must consist of at least 1 imaging modality: computed tomography (CT) or magnetic resonance imaging (MRI).
2.Be at least 18 years of age on the day of signing informed consent
3.Have an ECOG performance status of 0 to 1, to be performed within 3 days prior to the first dose of study treatment
4.Have a life expectancy of greater than 6 months
5.Male participants of childbearing potential must agree to use an adequate method of contraception as outlined in Appendix 3, for the course of the study through 180 days after the last dose of chemotherapy.
6.Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
7.Female participants of childbearing potential must be willing to use an adequate method of contraception as outlined in Appendix 3, for the course of the study through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater.
8.The participant provides written informed consent for the study. The participant may also provide consent for Future Biomedical Research. However, the participant may participate in the main study without participating in Future Biomedical Research.
9.Plan to proceed to surgery following pre operative chemotherapy based on standard staging studies per local practice.
10.Be willing to provide tissue from a tumor lesion at baseline and at time of surgery
11.Have adequate organ function as defined in the protocol. Specimens must be collected within 10 days prior to the start of study treatment.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 500
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 500

Exclusion criteria:
1.Has a history of (non infectious) pneumonitis that required steroids or has current pneumonitis
2.Has an active infection requiring systemic therapy
3.Has a diagnosis of immunodeficiency
4.Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
5.Has a known severe hypersensitivity (= Grade 3) to pembrolizumab, its active substance and/or any of its excipients. (Refer to the respective IB for a list of excipients.)
6.Has a known severe hypersensitivity (= Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.
7.Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
8.Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
9.Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
10.Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
11.Female participants: Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater.
Male participants: Is expecting to father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy.
12. Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase [DPD]), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
13. Has had an allogeneic tissue/solid organ transplant.
14. Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
15. A woman of child-bearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to receiving first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (ie, CTLA-4, OX-40, CD137) or has previously participated in a Merck pembrolizumab (MK-3475) clinical study.
17. Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy.
18.Is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of study treatment.
19.Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the f


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Cancer [C04]
Gastric or Gastroesophageal Junction Adenocarcinoma
MedDRA version: 21.0 Level: LLT Classification code 10056267 Term: Gastroesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intervention(s)

Trade Name: KEYTRUDA (pembrolizumab, MK-3475)
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: PEMBROLIZUMAB
CAS Number: 1374853-91-4
Current Sponsor code: MK-3475
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Trade Name: Cisplatin Accord 1 mg/mL
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: CISPLATIN
CAS Number: 15663-27-1
Other descriptive name: CISPLATIN
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 1-

Trade Name: Fluorouracil-GRY®
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLUOROURACIL
CAS Number: 51-21-8
Other descriptive name: FLUOROURACIL
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-

Trade Name: Fluorouracil
Pharmaceutical Form: Solution for injection
INN or Proposed INN: FLUOROURACIL
CAS Number: 51-21-8
Other descriptive name: FLUOROURACIL
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-

Trade Name: Capecitabine
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: CAPECITABINE
Other descriptive name: CAPECITABINE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-

Trade Name: Capecitabine
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: CAPECITABINE
Other descriptive name: CAPECITABINE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-

Trade Name: Docetaxel Aurobindo 20 mg/ml
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DOCETAXEL
CA
Primary Outcome(s)
Secondary Objective: Main Study (XP/FP), and Main Study (XP/FP) and FLOT Cohort
Combined:
1. To evaluate the safety and tolerability of pembrolizumab in combination with chemotherapy

Main Study (XP/FP):
2. To evaluate the disease-free survival (DFS) as assessed by investigator for participants who are disease free after surgery

Main Study (XP/FP) and FLOT Cohort Combined:
3. To evaluate OS
4. To evaluate EFS
Primary end point(s): Main study (XP/FP):
-Event free Survival (EFS) assessed by investigators
-Rate of Pathological Complete Response (pathCR)
-Overall Survival (OS)

FLOT Cohort:
- AEs; Study treatment discontinuations due to AEs
Timepoint(s) of evaluation of this end point: IA1: ~ 41 months after first participant randomized.
final pathCR rate analysis and interim EFS and OS analyses.
IA2: ~ 7 months after IA1.
Primary purpose: interim EFS and OS analyses

IA3:~ 12 months after IA2.
Primary purpose: final EFS analysis and interim OS analysis.
Final analysis (FA):~ 12 months after IA3.
Primary purpose: final OS analysis.
Main Objective: Main Study (XP/FP)
1. To evaluate event-free survival (EFS)
2. To evaluate the rate of pathological complete response based on central review.
3. To evaluate overall survival (OS)

FLOT Cohort
4. To evaluate the safety and tolerability of pembrolizumab in combination with docetaxel, oxaliplatin, 5-FU, and leucovorin (calcium folinate) (FLOT)
Secondary Outcome(s)
Secondary end point(s): Main study (XP/FP):
-Disease free Survival (DFS) assessed by investigators
-AEs; Study treatment discontinuations due to AEs

Main study (XP/FP) and FLOT Cohort Combined:
-Overall Survival (OS)
-Event free Survival (EFS) assessed by investigators
-AEs; Study treatment discontinuations due to AEs


Timepoint(s) of evaluation of this end point: IA1: ~ 41 months after first participant randomized.
Primary purpose: interim EFS and OS analyses.
IA2: ~ 7 months after IA1.
Primary purpose: interim EFS and OS analyses
IA3:~ 12 months after IA2.
Primary purpose: final EFS analysis and interim OS analysis.
Final analysis (FA):~ 12 months after IA3.
Primary purpose: final OS analysis.

DFS: Up to approximately 2 years

Safety: Throughout the study
Secondary ID(s)
3475-585
Source(s) of Monetary Support
Merck Sharp & Dohme LLC
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 25/08/2017
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history